Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.52 |
| ▸ | CA1 | P00915 | 5/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.52 |
| ▸ | CA2 | P00918 | 4/20 | 0.52 |
| ▸ | CA7 | P43166 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | STS | P08842 | 1/20 | 0.36 |
| ▸ | APLNR | P35414 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5121779 | 0.83 | CA12 (0.42) | CA12CA1CA14CA2CA7 | |
| SCHEMBL3762126 | 0.81 | CA12 (0.52) | CA12CA1CA14CA2CA7 | |
| SCHEMBL756075 | 0.81 | CA12 (0.52) | CA12CA1CA14CA2CA7 | |
| SCHEMBL13217304 | 0.81 | CA12 (0.52) | CA12CA1CA14CA2CA7 | |
| SCHEMBL25472477 | 0.79 | CA12 (0.50) | CA12CA1CA14CA2CA7 | |
| SCHEMBL1799649 | 0.79 | CA1 (0.50) | CA12CA1CA14CA2CA7 | |
| SCHEMBL29084558 | 0.79 | CA12 (0.50) | CA12CA1CA14CA2CA7 | |
| SCHEMBL2011562 | 0.79 | CA12 (0.50) | CA12CA1CA14CA2CA7 | |
| SCHEMBL29098389 | 0.79 | CA12 (0.50) | CA12CA1CA14CA2CA7 | |
| SCHEMBL14253505 | 0.77 | CA12 (0.58) | CA12CA1CA14CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 552 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624023-B2 | Sulfonylurea derivatives and uses thereof | NodThera Limited (GB) | 2026-05-12 | — | — | US | disclosed |
| US-12534458-B2 | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | MERCK SHARP & DOHME LLC (US) | 2026-01-27 | — | — | US | disclosed |
| US-20250388571-A1 | AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF | BIOLEXIS THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-3423433-B1 | SULFAMATE DERIVATIVE COMPOUNDS, PROCESSES FOR PREPARING THEM AND THEIR USES | BIO PHARM SOLUTIONS CO LTD (KR) | 2025-12-17 | — | — | EP | disclosed |
| EP-3983407-B1 | SULFONYLUREA DERIVATIVES AND USES THEREOF | NODTHERA LTD (GB) | 2025-11-12 | — | — | EP | disclosed |
| EP-4644392-A1 | PYRIDAZINE FUSED ARYL RING COMPOUND AND USE THEREOF | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2025-11-05 | — | — | EP | disclosed |
| US-12459925-B2 | Sulphonyl urea derivatives as NLRP3 inflammasome modulators | NodThera Limited (GB) | 2025-11-04 | — | — | US | disclosed |
| US-20250326713-A1 | INHIBITORS OF MsbA AS ANTIBIOTICS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4634186-A1 | 2,6,9-TRISUBSTITUTED PURINES | Astrazeneca AB (SE) | 2025-10-22 | — | — | EP | disclosed |
| US-12441744-B2 | 2,6,9-trisubstituted purines | ASTRAZENECA AB | 2025-10-14 | — | — | US | disclosed |
| WO-2000039089-A1 | 3-AZABICYCLO[3.1.0.] HEXANE DERIVATIVES AS OPIATE RECEPTORS LIGANDS | PFIZER LIMITED (GB) | 2000-07-06 | — | — | WO | disclosed |
| EP-0900791-A1 | TETRAZOLE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 1999-03-10 | — | — | EP | disclosed |
| US-5703243-A | Intermediates for pyrrolidylthiocarbapenem derivative | SHIONOGI SEIYAKU KABUSHIKI KAISHA (JP) | 1997-12-30 | — | — | US | disclosed |
| CN-1167484-A | Novel amidinonaphthyl derivative or salt thereof | YAMANOUCHI PHARMA CO LTD (JP) | 1997-12-10 | — | — | CN | disclosed |
| CN-1034571-C | A method for producing a pyrrolidire derivative | SHIONOGI & CO (JP) | 1997-04-16 | — | — | CN | disclosed |
| CN-1032257-C | Process for producing pyrrolidinethinyl carbapenem derivatives | SHIONOGI SEIYAKU KK (JP) | 1996-07-10 | — | — | CN | disclosed |
| CN-1113233-A | A method for producing a pyrrolidire derivative | SHIONOGI & CO (JP) | 1995-12-13 | — | — | CN | disclosed |
| US-5317016-A | Pyrrolidylthiocarbapenem derivative | SHIONOGI SEIYAKU KABUSHIKI KAISHA (JP) | 1994-05-31 | — | — | US | disclosed |
| CN-1071428-A | Pyrrolidinylthiocarbapenem derivatives | SHIONOGI & CO (JP) | 1993-04-28 | — | — | CN | disclosed |
| EP-0528678-A1 | A pyrrolidylthiocarbapenem derivative | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) | 1993-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12534458-B2 | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | CHRNA6, CHRNA7, CHRNA5 | CA12 4102/4885CA1 1368/4885CA14 4547/4885 |
| US-20250388571-A1 | AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF | PRKAB2, PRKAB1, PRKAR2B | CA12 4283/4885CA1 3591/4885CA14 4418/4885 |
| US-20250326713-A1 | INHIBITORS OF MsbA AS ANTIBIOTICS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MSRB3, ARSA, ABCG2 | CA12 4654/4885CA1 4834/4885CA14 4488/4885 |
| US-12441744-B2 | 2,6,9-trisubstituted purines | CDK2, CDK1, CCNT2 | CA12 4633/4885CA1 4041/4885CA14 4622/4885 |
| US-12624023-B2 | Sulfonylurea derivatives and uses thereof | PYCARD, NOD1, NLRP3 | CA12 3215/4885CA1 2460/4885CA14 3657/4885 |
| US-12459925-B2 | Sulphonyl urea derivatives as NLRP3 inflammasome modulators | NLRP3, NOD1, IL1B | CA12 4716/4885CA1 3624/4885CA14 4678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.